Mode
Text Size
Log in / Sign up

Acute exacerbation of chronic obstructive pulmonary disease

Part of Chronic Obstructive Pulmonary Disease

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for acute exacerbation of chronic obstructive pulmonary disease

12 trials tracked for acute exacerbation of chronic obstructive pulmonary disease: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 129 citations.

12Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 1 Other / NA 7
  1. Phase 4 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Completed · 129 cited
  2. Phase 3 TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial Completed · 102 cited
  3. Phase 3 Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD Completed · 14 cited
  4. Phase 4 Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD Completed
  5. Phase 2 Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) Completed
  6. N/A Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Pilot Study) Completed
Show 6 more trials
  1. N/A Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy Completed
  2. N/A Early Assisted Discharge for COPD Exacerbations With Telemonitoring. Completed
  3. N/A Acupuncture Treatment of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Completed
  4. N/A COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers Completed
  5. N/A Telehealth Pulmonary Rehabilitation for Hispanic and African-American Patients Admitted With Exacerbation of COPD Completed
  6. N/A Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Study 2) Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Acute exacerbation of chronic obstructive pulmonary disease: what the trials found

Management of COPD involves various pharmacological and rehabilitative approaches. Clinical trials evaluated the impact of Roflumilast on exacerbation rates, finding no statistically significant difference in the rate of moderate or severe exacerbations per patient per year (p=0.1634) or those requiring hospitalization/death (p=0.6354). Additionally, there was no significant difference in the rate of exacerbations treated with antibiotics (p=0.0884).

Pharmacological interventions include corticosteroids and bronchodilators; for example, Prednisone was evaluated regarding treatment failure at 90 days 3, and Theophylline ER was associated with changes in St. George Respiratory Questionnaire (SGRQ) scores 4. Antibiotic therapy comparisons between Levofloxacin and Prulifloxacin showed specific counts of therapeutic success at the end of a 10-day cycle 2.

Pulmonary rehabilitation programs, including home-based models, have been evaluated for their impact on quality of life and physical symptoms. Home-based pulmonary rehabilitation was associated with changes in EQ-5D scores 6 and significant improvements in emotional symptoms as measured by the Chronic Respiratory Questionnaire (CRQ) 11.

Recent results — preliminary, needs further review

  • MSTT1041A showed no statistically significant difference in the number of moderate to severe exacerbations compared to control 5.
  • Telehealth pulmonary rehabilitation was associated with a significant reduction in the composite of COPD hospital readmission/death within 6 months of discharge (p=<.05) 8.
  • Telemonitoring and telephone control were associated with statistically significant results regarding time until first exacerbation (p=<0.05) 9.
  • Formoterol was evaluated for its effect on Peak FEV1 and FVC following inhalation 12.

For the clinician treating this condition

  • Roflumilast did not demonstrate a statistically significant reduction in the frequency of moderate to severe exacerbations or those requiring hospitalization.
  • Home-based pulmonary rehabilitation is associated with improvements in emotional symptoms and changes in quality of life scores (EQ-5D).
  • Telehealth and telemonitoring interventions show potential for reducing hospital readmissions and influencing time to first exacerbation.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Chronic Obstructive Pulmonary Disease

Related studies from across the Chronic Obstructive Pulmonary Disease family.

Skeletal muscle dysfunction impacts exercise capacity and exacerbation risk in patients with COPD
Pulmonology & Critical Care Sys. Review
Skeletal muscle dysfunction impacts exercise capacity and exacerbation risk in patients with COPD Muscle Health Linked to Better Outcomes for COPD Patients
This narrative review explores the lung-muscle axis in patients with COPD, linking skeletal muscle dysfunction to impaired physical function…
Weak muscles can lead to lower exercise capacity and higher risk of flare-ups for people living with COPD.
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients
Gastroenterology Sys. Review
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients Aerosolized Amphotericin B Shows Promise for Lung Fungal Infections
This mini review synthesizes clinical experience regarding aerosolized antifungal therapies for various pulmonary fungal infections. It conc…
Aerosolized liposomal amphotericin B shows promise for preventing specific lung fungal infections in high-risk and immunocompromised patient…
Dysphagia affects 38.2% of COPD patients; advanced disease and tooth loss raise risk
Pulmonology & Critical Care Meta-analysis
Dysphagia affects 38.2% of COPD patients; advanced disease and tooth loss raise risk More than one-third of COPD patients struggle with swallowing
This meta-analysis of observational studies including 4608 patients with chronic obstructive pulmonary disease found a pooled dysphagia prev…
Nearly 40% of people with COPD experience dysphagia, a condition that makes swallowing difficult and can impact daily nutrition and safety.
Triple therapy improves SGRQ scores in stable COPD but increases pneumonia risk compared to dual bronchodilation
Pulmonology & Critical Care Sys. Review
Triple therapy improves SGRQ scores in stable COPD but increases pneumonia risk compared to dual bronchodilation Triple therapy shows some benefits for people with COPD
This systematic review and Bayesian network meta-analysis of inhaled maintenance therapies for stable COPD found that triple therapy provide…
Triple therapy may improve quality of life for people with COPD, but it also carries a higher risk of pneumonia.
Exercise reduces inflammatory markers in 45.6% of meta-analytic associations, but evidence quality is low
Pulmonology & Critical Care Sys. Review
Exercise reduces inflammatory markers in 45.6% of meta-analytic associations, but evidence quality is low Exercise Shows Link to Lower Inflammation in Chronic Diseases
This umbrella review of 61 meta-analyses (318 associations) found that exercise significantly reduced circulating inflammatory markers in 45…
New research shows that regular exercise may lower key markers of inflammation for people living with chronic conditions like heart disease …
Yoga and Baduanjin improve lung function while Tai Chi improves quality of life in COPD
Rheumatology Meta-analysis
Yoga and Baduanjin improve lung function while Tai Chi improves quality of life in COPD Yoga and Tai Chi may improve life for COPD patients
This systematic review and network meta-analysis of 4,720 stable COPD patients evaluated digital health interventions and traditional mind-b…
New analysis shows yoga can boost lung function while Tai Chi helps manage daily symptoms for people with chronic lung disease.
Resveratrol improves pulmonary function and reduces inflammation in animal models of chronic obstructive pulmonary disease
Drug Pipeline Meta-analysis
Resveratrol improves pulmonary function and reduces inflammation in animal models of chronic obstructive pulmonary disease Resveratrol shows promise for COPD in animal study
This meta-analysis of preclinical studies indicates that resveratrol significantly improves lung compliance and airflow while reducing pro-i…
A compound in grapes and red wine improved lung function and reduced inflammation in animals with COPD, but human trials are needed.
Stathmin implicated in cancer and non-neoplastic diseases, potential biomarker and therapeutic target
Drug Pipeline Sys. Review
Stathmin implicated in cancer and non-neoplastic diseases, potential biomarker and therapeutic target Stathmin Linked to Cancer Growth and Tissue Repair Processes
This systematic review synthesizes evidence on stathmin, a microtubule-regulating protein, across cancer and non-neoplastic diseases. Aberra…
Research shows stathmin plays a key role in both cancer cell behavior and the body's ability to repair skin, mucus membranes, and lung tissu…
High intensity exercise training improves dyspnoea management across multiple chronic respiratory and neuromuscular conditions
Psychiatry Sys. Review
High intensity exercise training improves dyspnoea management across multiple chronic respiratory and neuromuscular conditions High intensity exercise helps people with chronic breathing difficulties
This narrative review examines the role of exercise training, specifically higher intensities, for managing dyspnoea in patients with COPD, …
People living with conditions like COPD or Long-COVID may find relief from shortness of breath through specific types of high-intensity exer…
Inhaled treprostinil is the only approved therapy with randomized evidence for pulmonary hypertension associated with interstitial lung disease
Drug Pipeline Sys. Review
Inhaled treprostinil is the only approved therapy with randomized evidence for pulmonary hypertension associated with interstitial lung disease Inhaled treprostinil shows promise for specific types of lung disease
This narrative review examines pharmacological management of pulmonary hypertension associated with interstitial lung disease (PH-ILD) and i…
New research clarifies which treatments actually work for patients facing both pulmonary hypertension and scarring of the lungs.
Host-targeting antivirals offer a potential transformative treatment strategy for rhinovirus infection
Allergy & Immunology Sys. Review
Host-targeting antivirals offer a potential transformative treatment strategy for rhinovirus infection Host Targeting Antivirals May Offer New Strategy for Common Cold
This systematic review examines host-targeting antivirals (HTAs) as an alternative to direct-acting antiviral drugs for respiratory infectio…
New research explores how host-targeting antivirals could change how we treat common cold infections and help high-risk patients.
COPD and OSA overlap syndrome is associated with greater disease burden than either condition alone
Pulmonology & Critical Care Sys. Review
COPD and OSA overlap syndrome is associated with greater disease burden than either condition alone Overlapping lung and sleep conditions lead to worse health outcomes
This narrative review examines the pathophysiological mechanisms and clinical outcomes of COPD-OSA overlap syndrome. The authors conclude th…
People with both chronic lung disease and sleep apnea face a heavier burden of illness than those with only one condition.